EHT 1610

EHT 1610 is a potent inhibitor of DYRK , with IC 50 s of 0.36 nM ( DYRK1A ), 0.59 nM ( DYRK1B ), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis.In VitroEHT 1610 induces apoptosis of primary ALL cells that were resistant to cytarabine. EHT 1610 dose-dependently induces apoptosis in B- and T-cell lines and primary human pediatric. EHT 1610 (; 72 h) inhibits DYRK1A, results loss of DYRK1A-mediated FOXO1 and STAT3 signaling, leading to preferential cell death in leukemic B cells. EHT 1610 (2.5-10 μM; 4-5 h) inhibits phosphorylation of FOXO1, STAT3 and cyclin D3, thus regulates late cell-cycle progression, mitochondrial ROS and DNA damage, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MHH-CALL-4 cells Concentration: 0, 2.5, 5, 10 μM Incubation Time: 4, 5 hours Result: Reduced p-cyclin D3 (Thr283), and p-FOXO1 protein level in a dose-dependent manner.In VivoEHT 1610 (20 mg/kg/d; i.p.; twice a day; 3 weeks) shows antileukemia activity against in leukemic aggressive model in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Xenograft models of B-ALL in mice (12-14 weeks old)Dosage: 20 mg/kg Administration: Intraperitoneal injection; twice a day, 5 days on, 2 days off; 3 weeks Result: Reduced leukemic burden by approximately 8% and conferred a modest survival advantage.Form:SolidIC50& Target:IC50: 0.36 nM (DYRK1A), 0.59 nM (DYRK1B)

Specifications & Purity: EHT 1610 is a potent inhibitor of DYRK , with IC 50 s of 0.36 nM ( DYRK1A ), 0.59 nM ( DYRK1B ), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis.In VitroEHT 1610 induces apoptosis of primary ALL cells that were resistant to cytarabine. EHT 1610 dose-dependently induces apoptosis in B- and T-cell lines and primary human pediatric. EHT 1610 (; 72 h) inhibits DYRK1A, results loss of DYRK1A-mediated FOXO1 and STAT3 signaling, leading to preferential cell death in leukemic B cells. EHT 1610 (2.5-10 μM; 4-5 h) inhibits phosphorylation of FOXO1, STAT3 and cyclin D3, thus regulates late cell-cycle progression, mitochondrial ROS and DNA damage, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MHH-CALL-4 cells Concentration: 0, 2.5, 5, 10 μM Incubation Time: 4, 5 hours Result: Reduced p-cyclin D3 (Thr283), and p-FOXO1 protein level in a dose-dependent manner.In VivoEHT 1610 (20 mg/kg/d; i.p.; twice a day; 3 weeks) shows antileukemia activity against in leukemic aggressive model in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Xenograft models of B-ALL in mice (12-14 weeks old)Dosage: 20 mg/kg Administration: Intraperitoneal injection; twice a day, 5 days on, 2 days off; 3 weeks Result: Reduced leukemic burden by approximately 8% and conferred a modest survival advantage.Form:SolidIC50& Target:IC50: 0.36 nM (DYRK1A), 0.59 nM (DYRK1B)

Grade: Moligand™

Molecular Formula: C18H14FN5O2S

Molecular Weight: 383.40

PubChem CID: 71529602

Isomeric SMILES: COC1=CC(=C(C=C1)NC2=NC=NC3=C2C4=C(C=C3)N=C(S4)C(=N)OC)F

Storage Temperature: Protected from light;Store at -20°C;Argon charged

Shipped in: Ice chest + Ice pads

UPC:

51442306

Weight:

1.06 Ounces

HazmatClass:

Yes

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

E651619-1mg

Country of Origin:

China

CAS:

1425945-60-3

Product Size:

1mg

Harmonized Tariff Code:

2931.90.90